Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California. Show more

Location: 680 East Colorado Boulevard, Pasadena, CA, 91101, United States | Website: https://lixte.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

2.495M

52 Wk Range

$0.64 - $3.00

Previous Close

$0.90

Open

$1.03

Volume

12,688,253

Day Range

$0.90 - $1.54

Enterprise Value

4.544M

Cash

1.385M

Avg Qtr Burn

-735.9K

Insider Ownership

18.43%

Institutional Own.

15.84%

Qtr Updated

03/31/25